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Martin D. Berger d, Inti Zlobec a,1, Alessandro Lugli a,*,1 
a Institute of Pathology, University of Bern, Bern, Switzerland 
b Institute of Pathology, Aarau Cantonal Hospital, Aarau, Switzerland 
c University of Zürich, Institute of Pathology, City Hospital Triemli, Zürich, Switzerland 
d Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland   
A R T I C L E  I N F O   
Keywords: 






A B S T R A C T   
Background: During the last decades, the management for metastatic colorectal cancer patients has improved due 
to novel therapeutic approaches. A mismatch-repair deficient status seems to favour a better response to 
checkpoint inhibitor therapy, but the question arises whether a specific subgroup of stage IV patients with 
mismatch-repair (MMR) proficient status should also be considered. RHAMM (Receptor for Hyaluronic Acid 
Mediated Motility/HAMMR/CD168) is characterized by tumor progression and immunogenicity. Therefore, the 
aim of this study is to determine whether RHAMM within the CRLM of MMR-proficient patients correlate with a 
more immunological microenvironment, represented by cytotoxic T-cells, PD-1 and PD-1. 
Methods: Two patient cohorts of liver metastases from MMR colorectal cancers were included into the study (n =
81 and 76) using ngTMA® technology and immunohistochemically analyzed for RHAMM, cytotoxic T-cells 
(CD8+), PD-1/PD-L1, intrametastatic budding (IMB) and perimetastatic budding (PMB). 
Results: RHAMM-positive IMB was linked to a higher PD-L1 expression (r = 0.32; p = 0.233 and r = 0.28; p =
0.044) in the center and periphery of the metastasis and RHAMM-positive PMB was associated with a higher 
expression of PD-1 (r = 0.33; p = 0.0297), and especially PD-L1 (r = 0.604; p < 0.0001 and r = 0.43; p = 0.003) 
in the center and periphery of the metastasis. IMB and PMB were additionally associated with a higher count of 
CD8+ T-cells (p < 0.0001; r = 0.58; p < 0.0001; r = 0.53). 
Conclusions: The RHAMM status can be assessed in IMB/PMB either in biopsies or in resections of colorectal 
cancer liver metastases. A positive RHAMM status in IMB and/or PMB may be a potential indicator for a 
checkpoint inhibitor therapy for stage IV colorectal cancer patients with MMR proficient status.   
1. Introduction 
Tumor budding is a histopathological prognostic biomarker and its 
standardized reporting was proposed by the International Tumor 
Budding Consensus Conference (ITBCC) in 2016 [1]. Tumor budding is 
now included in the UICC’s TNM and WHO classifications [2,3] and also 
in important guidelines such as the European Society of Medical 
Oncology (ESMO) [4], National Comprehensive Cancer Network 
(NCCN) [5], International Collaboration on Cancer Reporting (ICCR) 
[6], Royal College of Pathologists (RCPath) [7] and College of American 
Pathologists (CAP) [8]. Tumor budding along with other 
clinico-pathological parameters plays a role in the management of 
colorectal cancer (CRC) patients especially in two clinical scenarios: 
first, in pT1 CRC tumor budding is associated with the presence of lymph 
node metastases and is therefore a potential indicator for an oncologic 
resection [9–11]; second, in stage II colon cancer with high grade 
budding (BD3), adjuvant therapy may be considered [9,12]. 
Based on the literature tumor budding may also be included in two 
additional clinical scenarios, namely the assessment of intratumoral 
budding (ITB) in preoperative biopsies in colon and rectal cancer [13] 
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and especially in colorectal cancer liver metastases (CRLM) of stage IV 
CRC patients [14]. While the promising role of ITB in preoperative CRC 
biopsies is underlined by several studies, the assessment and function of 
tumor budding in CRLM requires more evidence before consideration for 
patient management. In a recent study, Fonseca et al. have demonstrated 
the prognostic impact of tumor budding in CRLM in univariate analysis 
[15]. Additionally, we proposed the terms intrametastatic (IMB) and 
perimetastatic budding (PMB) based on H&E staining for assessment of 
tumor budding in CRLM [14]. 
Over the last 20 years, the prognosis for metastatic CRC (mCRC) has 
improved and the median overall survival (OS) for patients with mCRC 
is approximately 30 months based on phase III trials and large obser-
vational series or registries [16]. Some data have shown a potential 
benefit of immune checkpoint blockade with pembrolizumab in patients 
with a deficient mismatch-repair status (dMMR) in mCRC compared to 
those with a proficient mismatch-repair status (pMMR) [17,18]. 
Nevertheless, the question arises whether mCRC patients with 
pMMR status may still be candidates for a checkpoint inhibitor therapy. 
Therefore, the objective of the present study was to evaluate biomarkers 
of CRLM in pMMR cases according to the following hypothesis: the 
Receptor for Hyaluronic Acid Mediated Motility (RHAMM/HMMR/ 
CD168) has been shown to be a strong independent prognostic factor in 
CRC [19–22], its overexpression in cancer cells correlates with increased 
migration and invasion and its downregulation abolishes metastasis in 
mouse models [23]. Additionally, several studies have postulated a 
potential immunogenic role of RHAMM [24–26]. Taken together, the 
aim of this study is to determine whether RHAMM positive cells 
(including IMB and PMB) within the CRLM of MMR-proficient patients 
correlate with a more immunological microenvironment, represented by 
cytotoxic T-cells, PD-1 and PD-1. The specific selection of cytotoxic 
T-cells is based on a previous study showing the role of CD8 positive 
T-cells in the surroundings of tumor buds [27]. 
2. Material and methods 
2.1. Patients 
Two collectives of patients with CRLM from 2002 to 2016 were 
included into the study. In the first, 81 patients diagnosed at the Insel-
spital, University Hospital Bern, Switzerland, and for whom tissue 
blocks were available from metastatic lesions were entered into this 
study. All cases were re-reviewed for histopathology and used to 
construct a multi-punch tissue microarray. A second collective of 76 
CRLM patients was included and used to study expression of biomarkers 
on whole slides. Eighteen cases were common to both cohorts. Upon re- 
review of the H&E slides, the tumor block with the largest metastasis 
was included in downstream analysis. Clinicopathological information 
can be found in Table 1. All the CRLM cases were mismatch-repair 
proficient. No information on overall or progression-free survival were 
included in this study. This retrospective study was approved by the 
local ethics committee of the Canton of Bern (#2020− 00498) 
2.2. Tissue microarray 
For the first collective, upon re-review of tissue slides, tissue blocks 
corresponding to selected representative areas of the metastatic lesion 
were retrieved from the archives of the Institute of Pathology, University 
of Bern. A fresh H&E section was made and all slides were scanned 
(Pannoramic P250, Budapest, Hungary). Each scan was annotated in 
two regions of interest (ROI), namely the metastasis center and the 
metastasis front and both ROIs were annotated twice. In a few cases, 
where >1 metastasis was available, more ROIs were made. The final 
number of ROIs was 196. Using a tissue microarrayer, the digital ROIs 
from the scans were aligned with images of the tissue blocks, ROIs were 
cored out and transferred into two sets of next-generation Tissue 
Microarrays (ngTMA®). In order to account for possible tumor 
heterogeneity, two punches were taken from the center of the metastasis 
and two punches from the periphery, in each case. An H&E of each was 
sectioned. 
2.3. Immunohistochemistry 
All ngTMAs® were cut at 2.5 um. Whole slides of the CRLM in the 
second collective were also sectioned and stained similarly. 
All immunostainings was performed by automated staining using 
Bond RX (Leica Biosystems) immunostainer and dewaxed in Bond 
dewax solution (Leica Biosystems). The antigen retrieval was performed 
for all sections in Tris buffer at 95◦ for 30 min (Leica Biosystems). For all 
single immunostainings, PD-1 (Cell Marque, clone NAT105, Ref 315M- 
95) diluted at 1:100, PD-L1 (Cell Signaling, clone E1L3N, Ref 13684) 
diluted at 1:400 and RHAMM (Abcam, Ref ab108339) diluted at 1:250 
were in incubated at RT for 30 min. Then, all samples were incubated 
HRP (Horseradish Peroxidase)-polymer for 15 min and subsequent 
visualized using 3,3-Diaminobenzidine (DAB) as brown chromogen 
(Bond polymer refine detection, Leica Biosystems, Ref DS9800) for 10 
min. 
For double immunostaining, all primary antibodies were incubated 
sequentially: first step, mouse PanCK antibody (Agilent, clone AE1/AE3, 
Ref M351501− 2) was diluted 1:400, incubated for 30 min. Then, sam-
ples were incubated in HRP and DAB, as above. On a second step, mouse 
CD8 antibody (Dako- Agilent, clone C8/144B, Ref M7103) was diluted 
1:100, incubated for 30 min. Secondary antibody, AP (Alkaline 
phosphatase)-polymer for 15 min, and visualized using fast red as red 
chromogen (Red polymer refine Detection, Leica Biosystems, Ref 
DS9390). 
In common for all, the samples were counterstained with Haema-
toxylin and mounted with Aquatex (Merck). Slides were scanned and 
photographed using Pannoramic 250 (3DHistech). Representative im-
ages are shown in Fig. 1. 
2.4. Biomarker assessment 
Tumor budding was evaluated in both the ngTMA® slides and whole 
slides. In the former, the number of tumor buds in each punch was 
recorded and then the punch with the maximum value of budding was 
Table 1 
Characteristics of stage IV CRC patients in cohort 1 and 2.    
Cohort 1 (n =
81) 
Cohort 2 (n =
76) 
Gender Male 55 (67.9 %) 44 (57.9 %)  
Female 26 (32.1 %) 32 (42.1 %)  
Age at metastasis 
diagnosis 
Mean, range 61.4 (26− 86) 63 (40− 81)  
Neoadjuvant therapy None 8 (9.9 %) 9 (11.8 %)  
Yes 21 (26.0 %) 18 (22.2 %)  
Unknown 52 (64.2 %) 49 (60.5 %)  
Metastasis Synchronous 55 (67.9 %) 40 (52.6 %)  
Metachronous 25 (30.9 %) 34 (44.7 %)  
Size of largest metastasis 
(cm) 
Mean, range 4.0 (0.5− 16) 3.9 (0.2− 16) 
% necrosis Mean, range 26.3 (5− 60) 30.7 (0− 90) 
% fibrosis Mean, range 25.5 (5− 60) 30 (5− 95)  
Growth pattern    
% desmoplastic Mean, range 39.9 (0− 100) 55.4 (0− 100) 
% replacement Mean, range 57.1 (0− 100) 40.1 (0− 100) 
% pushing Mean, range 3.0 (0− 96) 4.5 (0− 75) 
% sinusoidal Mean, range 0% 0% 
% portal Mean, range 0% 0%  
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used for analysis of both tumor budding and CD8+ T-lymphocytes. For 
the latter, we assessed the average number of buds in 10 high-power 
fields at the invasion front (perimetastatic budding, PMB) and within 
the main tumor body (intrametastatic budding, IMB) based on H&E 
staining [14]. The histopathological growth patterns (desmoplastic, 
pushing and replacement subtype) were scored according to the inter-
national consensus guidelines published in 2017 [28]. 
For RHAMM, the percentage of immunoreactive (RHAMM-positive) 
tumor cells over the total number of tumor cells was evaluated in both 
TMA punches (again, the average was taken across tumor area) and 
whole slides [22,29]. For PD-1 and PD-L1, a previously published 
scoring method based on 4 grades was used to semi-quantify the PD-L1 
in the tumor stroma (from 0 to 3) and across multiple punches from the 
same tissue area, used the median value for analysis [30,31]. 
2.5. Statistics 
Spearman’s correlation coefficient was used to determine the 
strength of the relationships between all quantitative or ordinal vari-
ables. P-values were two-sided and considered statistically significant 
when <0.05. All analyses were carried out using SAS V9.4. 
3. Results 
IMB was associated with a higher count of CD8+ T-cells (p < 0.0001; 
r = 0.58) as well as with replacement tumor growth pattern (p =
Fig. 1. Staining examples of the selected bio-
markers for the present study: Presence of 
intrametastatic (A) and perimetastatic (B) CD8 
positive T-Cells (red). Cytokeratin staining 
(brown) is only used for visualization, but not 
for assessment of tumor buds. Intrametastatic 
(C) and perimetastatic (D) tumor buds 
expressing RHAMM. PDL-1 positivity mainly in 
the intrametastatic (E) and perimetastatic (F) 
tumoral stroma in comparison to the expression 
of the neoplastic cell population. Scale bar 100 
μm, 5x magnification.   
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0.0049). Consequently, a desmoplastic growth pattern was negatively 
correlated with the number of tumor buds (r=-0.38; p = 0.0004). 
RHAMM-positive IMB were linked to a higher PD-L1 expression (r =
0.32; p = 0.233 and r = 0.28; p = 0.044) in the center and periphery of 
the metastasis. PMB was also correlated with a higher CD8+ T-cell count 
(p < 0.0001; r = 0.53) but not with any particular growth pattern. 
RHAMM-positive PMB was similarly associated with a higher expression 
of PD-1 (r = 0.33; p = 0.0297), and especially PD-L1 (r = 0.604; p <
0.0001 and r = 0.43; p = 0.003) in the center and periphery of the 
metastasis and in general, the expression of RHAMM, regardless of 
location within the lesion was linked to a greater expression pf PD-L1 (r 
= 0.32; p = 0.0059 and r = 0.451; p = 0.0001; center and front of 
metastasis respectively). These interactions are illustrated in Fig. 2. 
4. Discussion 
In the era of personalized healthcare, pathology has an important 
role in the course of a promising biomarker to make its way from hy-
pothesis to implementation in daily practice. In that sense, we embarked 
on this study using two CRLM cohorts and hypothesis-driven biomarkers 
to achieve a clear aim, namely outline a potential basis for multi-centric 
retrospective and prospective clinical trials in stage IV colorectal cancer 
patients with pMMR status. The obtained results are promising and 
worth being validated in further clinical trials. In summary, the assess-
ment of RHAMM in IMB and/or PMB in biopsies or resections of CRLM 
could lead to the selection of stage IV CRC patients with pMMR status 
who could potentially benefit from immunotherapies. The summarized 
results are supported by the following clinico-pathological aspects: 
First, tumor budding is an independent prognostic biomarker in all 
CRC stages based on robust data in the literature [32]. Nevertheless, 
tumor budding is included in international classifications and guidelines 
only for two clinical scenarios, namely as potential indicator for an 
oncologic resection in pT1 CRC or for a postoperative therapy in stage II 
CRC [9]. Recently, several studies focus on two additional clinical sce-
narios which need further data before their implementation in daily 
practice. In preoperative biopsies of rectal cancer patients, tumor 
budding is associated with tumor progression and decreased regression 
grade and is therefore along with other clinico-pathological parameters 
a potential indicator for neo-adjuvant therapy [33,13]. The available 
data on the role of tumor budding in CRLM are still in a preliminary 
phase and the present study would be just the third analysis on the 
potential role of tumor budding in CRLM. In 2018, Fonseca et al. 
Fig. 2. Visualisation of the interaction between RHAMM, cytotoxic T-cells, PD1/PDL-1, perimetastatic and intrametastatic tumor budding in colorectal cancer 
liver metastases. 
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described for the first time the role of tumor budding in CRLM [15]. 
Tumor budding was associated with portal invasion, infiltrative border 
and survival in univariate, but not in multivariate analysis [15]. Our 
own research group systematically investigated on the possibilities for 
assessment of tumor budding in CRLM and implemented the terms IMB 
and PMB in 2019 [14]. We concluded that tumor budding assessment in 
CRLM is definitely challenging in cases without desmoplastic stroma 
reaction or accentuated ductular proliferation and proposed therefore to 
score tumor budding based on H&E staining and avoid immunohisto-
chemistry [14]. According to the international consensus guidelines for 
scoring the histopathological growth patterns of liver metastasis pub-
lished in 2017, the desmoplastic, pushing and replacement subtypes are 
the most frequently observed variants [28]. The combining of the 
IMB/PMB concept and the consensus patterns revealed interesting 
pathogenetic aspects. The growth pattern subtypes are assessed at the 
periphery of the metastasis; the lack of a perimetastatic desmoplastic 
stroma reaction does not exclude a high IMB count, which is supported 
by the association of IMB with replacement tumor growth pattern. A 
possible explanation could be a switch from PMB to IMB in case there is 
no desmoplastic stroma at the periphery, a mechanism that would allow 
to the CRLM to keep tumor progression. This hypothesis and observation 
should be followed and definitely needs further functional data. 
Second, the biomarkers included in the study, RHAMM, cytotoxic T- 
cells and PD1/PD-L1, were selected according to the data in the litera-
ture. RHAMM is a multi-functional protein, typically activated in wound 
healing [34], and involved in different signalling pathways by binding 
proteins such as FAK [35], Src [36] or ERK [37,38]. Additionally, 
RHAMM activation leads to regulation of mitotic spindle integrity, cell 
cycle progression, reorganization and degradation of the extracellular 
matrix [23]. In CRC, RHAMM is an independent prognostic factor and its 
expression by tumor buds increases motility, dissemination and infil-
tration of lymph and blood vessels [22,29,19]. These pathogenetic fea-
tures of RHAMM in CRC were supported by a functional study showing 
that RHAMM downregulation essentially abolishes metastases in mouse 
models [23]. An interesting additional aspect is the potential immuno-
genic aspect of RHAMM reflected by its association with an increased 
T-cell lymphocyte infiltration and normally detected in dMMR CRC [26, 
24,25,21]. Not surprisingly, because of its link to a prominent peritu-
moral T-cell infiltration, dMMR status is considered a surrogate of the 
PD1/PD-L1 status and therefore an indicator for a checkpoint inhibitor 
therapy in stage IV CRC [17]. One important rationale for personalised 
healthcare is to stratify patients into subgroups which qualify for a 
specific therapeutic approach and indeed, there is enough evidence in 
the literature that immune infiltration and microsatellite status are in-
dependent of each other [39,40]. In that line, the obtained results in this 
study seem to be promising by proposing a specific subgroup of stage IV 
CRC patients with pMMR status and RHAMM expression in IMB/PMB 
which may qualify for a checkpoint inhibitor therapy. 
The main goal of this manuscript is clearly not to present a prog-
nostic or predictive analysis, but to test preliminary a potential 
biomarker which can be validated in well-defined stage IV CRC multi- 
centric retrospective and prospective trials. Additionally, it has to be 
stated that the sample size in the present study is clearly too small and 
not fully characterized to draw definitive conclusions, but nevertheless 
the obtained results seem to be quite promising: RHAMM could be 
potentially assessed in IMB and PMB of CRLM biopsies or resections, 
respectively. The question which needs to be answered now is: do 
RHAMM positive CRLM cases with pMMR status benefit from immu-
notherapy in comparison to RHAMM negative CRLM cases? 
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